Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.54 |
| ▸ | RYR2 | Q92736 | 1/20 | 0.54 |
| ▸ | DRD2 | P14416 | 5/20 | 0.48 |
| ▸ | DRD3 | P35462 | 5/20 | 0.48 |
| ▸ | DRD1 | P21728 | 5/20 | 0.48 |
| ▸ | DRD4 | P21917 | 4/20 | 0.48 |
| ▸ | DRD5 | P21918 | 4/20 | 0.48 |
| ▸ | HTR2C | P28335 | 4/20 | 0.46 |
| ▸ | HTR2B | P41595 | 3/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
| ▸ | PNMT | P11086 | 1/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29758918 | 0.93 | KCNH2 (0.54) | KCNH2RYR2DRD2DRD3DRD1 | |
| SCHEMBL4859823 | 0.93 | KCNH2 (0.54) | KCNH2RYR2DRD2DRD3DRD1 | |
| Hydrochloric Acid SCHEMBL17965624 | 0.92 | KCNH2 (0.53) | KCNH2RYR2DRD2DRD3DRD1 | |
| SCHEMBL746109 | 0.89 | HTR2C (0.57) | KCNH2RYR2DRD2DRD3HTR2C | |
| SCHEMBL29558442 | 0.89 | HTR2C (0.57) | KCNH2RYR2DRD2DRD3HTR2C | |
| Hydrochloric Acid SCHEMBL31062521 | 0.88 | HTR2C (0.55) | KCNH2RYR2HTR2CHTR2BHTR2A | |
| Hydrochloric Acid SCHEMBL1124555 | 0.88 | HTR2C (0.55) | KCNH2RYR2HTR2CHTR2BHTR2A | |
| Formaldehyde SCHEMBL30554785 | 0.85 | PNMT (0.55) | KCNH2RYR2HTR2CHTR2BHTR2A | |
| SCHEMBL8467911 | 0.82 | CD274 (0.59) | KCNH2RYR2DRD2DRD3DRD1 | |
| SCHEMBL532484 | 0.82 | CD274 (0.59) | KCNH2RYR2DRD2DRD3DRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4660181-A1 | NAV1.7- AND/OR NAV1.8-INHIBITING HYDRAZIDES, PROCESSES FOR THE PREPARATION THEREOF, COMPOSITIONS, USES, METHODS FOR TREATMENT USING SAME, AND KITS | Eurofarma Laboratórios S.A. (BR) | 2025-12-10 | — | — | EP | disclosed |
| WO-2024159284-A1 | NAV1.7- AND/OR NAV1.8-INHIBITING HYDRAZIDES, PROCESSES FOR THE PREPARATION THEREOF, COMPOSITIONS, USES, METHODS FOR TREATMENT USING SAME, AND KITS | EUROFARMA LABORATÓRIOS S.A. (BR) | 2024-08-08 | — | — | WO | disclosed |
| US-RE49481-E1 | Compounds for the treatment and prophylaxis of respiratory syncytial virus disease | HOFFMANN-LA ROCHE INC. (US) | 2023-04-04 | — | — | US | disclosed |
| US-11180482-B2 | Anilinopyrimidines as haematopoietic progenitor kinase 1 (HPK1) inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2021-11-23 | — | — | US | disclosed |
| WO-2018102366-A1 | ANILINOPYRIMIDINES AS HAEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) INHIBITORS | ARIAD PHARMACEUTICALS, INC. (US) | 2018-06-07 | — | — | WO | disclosed |
| EP-2742039-B1 | COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS DISEASE | HOFFMANN LA ROCHE (CH) | 2015-09-16 | — | — | EP | disclosed |
| US-8871756-B2 | Compounds for the treatment and prophylaxis of Respiratory Syncytial Virus disease | HOFFMANN-LA ROCHE INC. (US) | 2014-10-28 | — | — | US | disclosed |
| EP-2742039-A1 | COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS DISEASE | F. Hoffmann-La Roche AG (CH) | 2014-06-18 | — | — | EP | disclosed |
| US-20130196974-A1 | COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS DISEASE | HOFFMANN-LA ROCHE INC. | 2013-08-01 | — | — | US | disclosed |
| WO-2013020993-A1 | COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2013-02-14 | — | — | WO | disclosed |
| WO-2008144483-A2 | AGENTS FOR TREATING DISORDERS INVOLVING MODULATION OF RYANODINE RECEPTORS | ARMGO PHARMA, INC. (US) | 2008-11-27 | — | — | WO | disclosed |
| WO-2008144483-A2 | AGENTS FOR TREATING DISORDERS INVOLVING MODULATION OF RYANODINE RECEPTORS | ARMGO PHARMA, INC. (US) | 2008-11-27 | — | — | WO | disclosed |
| WO-2008054605-A2 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | MERCK & CO., INC. (US) | 2008-05-08 | — | — | WO | disclosed |
| WO-2008051547-A1 | FUSED BICYCLIC DERIVATIVES OF 2,4-DIAMINOPYRIMIDINE AS ALK AND C-MET INHIBITORS | CEPHALON, INC. (US) | 2008-05-02 | — | — | WO | disclosed |
| EP-1070714-A9 | AMIDINE COMPOUNDS | JAPAN TOBACCO INC. (JP) | 2005-10-19 | — | — | EP | disclosed |
| EP-1070714-B1 | AMIDINE COMPOUNDS | JAPAN TOBACCO INC (JP) | 2004-08-04 | — | — | EP | disclosed |
| US-20040006099-A1 | Amidine compounds | JAPAN TOBACCO INC. | 2004-01-08 | — | — | US | disclosed |
| US-6562828-B1 | Novel amidine compound having a blood coagulation factor Xa inhibitory activity | JAPAN TOBACCO INC. (JP) | 2003-05-13 | — | — | US | disclosed |
| EP-1122252-A1 | NITROGENOUS FUSED HETEROCYCLE COMPOUNDS, PROCESS FOR THE PREPARATION THEREOF AND AGENTS CONTAINING THE SAME | Takeda Chemical Industries, Ltd. (JP) | 2001-08-08 | — | — | EP | disclosed |
| EP-1070714-A1 | AMIDINE COMPOUNDS | JAPAN TOBACCO INC. (JP) | 2001-01-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040006099-A1 | Amidine compounds | F2, SERPINC1, F12 | KCNH2 1760/4885RYR2 2760/4885DRD2 2615/4885 |
| US-20130196974-A1 | COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS DISEASE | CFTR, H1-10, RECQL | KCNH2 1726/4885RYR2 2600/4885DRD2 2328/4885 |
| US-11180482-B2 | Anilinopyrimidines as haematopoietic progenitor kinase 1 (HPK1) inhibitors | STK16, STK4, STK26 | KCNH2 3880/4885RYR2 4408/4885DRD2 3999/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.